MedTrace Logo

Nativis Voyager for Newly Diagnosed GBM

NCT03276286 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2023-02-02

No results posted yet for this study

Summary

This feasibility study will assess the effects of the Nativis Voyager therapy in patients newly diagnosed with GBM. The study will enroll and treat up to 32 subjects and will be combined with standard of care radiotherapy and temozolomide.

Conditions

Interventions

DEVICE

Nativis Voyager

Nativis Voyager treatment combined with standard of care radiotherapy and temozolomide

Sponsors & Collaborators

  • Nativis, Inc.

    lead INDUSTRY

Principal Investigators

  • Donna Morgan Murray, PhD · Nativis, Inc.

Study Design

Allocation
NA
Purpose
DEVICE_FEASIBILITY
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-10
Primary Completion
2022-05-31
Completion
2022-05-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03276286 on ClinicalTrials.gov